IMDX (Insight Molecular Diagnostics) Cyclically Adjusted Book per Share: $9.02 (As of Mar. 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.40
GF Value $1.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Cyclically Adjusted Book per Share?

Insight Molecular Diagnostics IMDX -3.23% 49 Cyclically Adjusted Book per Share is $9.02 as of Mar. 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Insight Molecular Diagnostics's adjusted book value per share for the three months ended in Mar. 2026 was $-0.331. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.02 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Insight Molecular Diagnostics's average Cyclically Adjusted Book Growth Rate was -7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-06-26), Insight Molecular Diagnostics's current stock price is $5.40. Insight Molecular Diagnostics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $9.02. Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio of today is 0.60.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Insight Molecular Diagnostics was 0.82. The lowest was 0.20. And the median was 0.33.


Insight Molecular Diagnostics  (NAS:IMDX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.40/9.02
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Insight Molecular Diagnostics was 0.82. The lowest was 0.20. And the median was 0.33.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Insight Molecular Diagnostics Cyclically Adjusted Book per Share Related Terms


Insight Molecular Diagnostics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Cyclically Adjusted Book per Share Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 9.83 9.04

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.71 9.55 9.37 9.04 9.02

IMDX vs BDSX, XGN, FONR: Cyclically Adjusted Book per Share Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio falls into.


IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insight Molecular Diagnostics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.331/330.2130*330.2130
=-0.331

Current CPI (Mar. 2026) = 330.2130.

Insight Molecular Diagnostics Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.512 241.018 4.812
201609 8.843 241.428 12.095
201612 6.863 241.432 9.387
201703 5.976 243.801 8.094
201706 3.820 244.955 5.150
201709 5.123 246.819 6.854
201712 2.799 246.524 3.749
201803 4.771 249.554 6.313
201806 3.475 251.989 4.554
201809 3.700 252.439 4.840
201812 1.684 251.233 2.213
201903 14.693 254.202 19.086
201906 12.891 256.143 16.619
201909 11.287 256.759 14.516
201912 10.813 256.974 13.895
202003 11.724 258.115 14.999
202006 11.780 257.797 15.089
202009 10.300 260.280 13.067
202012 9.688 260.474 12.282
202103 23.983 264.877 29.899
202106 22.734 271.696 27.630
202109 21.560 274.310 25.954
202112 14.141 278.802 16.749
202203 12.352 287.504 14.187
202206 14.038 296.311 15.644
202209 12.959 296.808 14.418
202212 5.781 296.797 6.432
202303 6.360 301.836 6.958
202306 5.291 305.109 5.726
202309 4.547 307.789 4.878
202312 2.478 306.746 2.668
202403 1.401 312.332 1.481
202406 1.698 314.175 1.785
202409 0.726 315.301 0.760
202412 -0.703 315.605 -0.736
202503 0.357 319.799 0.369
202506 0.038 322.561 0.039
202509 -0.321 324.800 -0.326
202512 -1.097 324.054 -1.118
202603 -0.331 330.213 -0.331

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $9.02 mean?
Insight Molecular Diagnostics (IMDX) has a Cyclically Adjusted Book per Share of $9.02 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' Cyclically Adjusted Book per Share too high?
Insight Molecular Diagnostics' current Cyclically Adjusted Book per Share is $9.02. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Cyclically Adjusted Book per Share compare to BDSX and XGN?
Insight Molecular Diagnostics' Cyclically Adjusted Book per Share of $9.02 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Book per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Cyclically Adjusted Book per Share is $9.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.40 — trading 328.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is $9.02. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Cyclically Adjusted Book per Share is $9.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.40 is trading 328.6% above its estimated GF Value™ of $1.26. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Cyclically Adjusted Book per Share: $9.02
  • GF Value™: $1.26 vs. price of $5.40 (328.6% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.40
Price
$1.26
GF Value